A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Launched by H. LUNDBECK A/S · May 31, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called eptinezumab to see if it can help reduce the number of days children and teenagers experience episodic migraines, which are headaches that come and go rather than being constant. The trial is currently looking for participants aged 2 to 17 who have been diagnosed with migraines for at least six months. To be eligible, participants must have had fewer than 14 headache days in the past month, and at least 4 of those must have been migraine days as tracked in a headache diary.
If your child participates, they will be asked to complete a headache diary for 28 days to record their headache days. This helps the researchers understand how well eptinezumab works. Participants will also receive regular check-ins with healthcare providers throughout the study. It's important to note that children with certain other types of headaches, neurological disorders, or untreated psychiatric conditions may not be eligible for this trial. Overall, this study aims to find effective ways to help young people manage their migraines better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of migraine (with or without aura) according to the International Classification of Headache Disorders, 3rd edition (ICHD-3; in the opinion of the investigator) with history of migraine headaches of at least 6 months prior to the Screening Visit.
- • During the 28-day screening period, the participant (and their parent/caregiver, when applicable) must adequately complete the headache eDiary (≥23 of the 28 days) following the day of the Screening Visit.
- • During the 28-day screening period, the participant must have ≤14 headache days, of which at least 4 are migraine days as documented in the eDiary.
- Exclusion Criteria:
- • History or diagnosis of chronic tension-type headache, hypnic headache, cluster headache, hemicrania continua, new daily persistent headache, or unusual migraine subtypes (previously referred to as complicated migraine), such as hemiplegic migraine (sporadic and familial), migraine with brainstem aura, recurrent painful ophthalmic neuropathy, or migraine with neurological accompaniments that are not typical of migraine aura (diplopia, altered consciousness, or long duration, e.g., \>60 min).
- • History of moderate or severe head trauma or other neurological disorder or systemic medical disease that is, in the investigator's opinion, likely to affect the functions of the central nervous system.
- • Current psychiatric condition that is uncontrolled and/or untreated for a minimum of 6 months prior to the Screening Visit. Participants with a lifetime history of psychosis and/or mania are excluded.
- • Any other disorder for which the treatment takes priority over treatment of migraine or is likely to interfere with study treatment or impair treatment compliance.
- • Other inclusion and exclusion criteria may apply.
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Madrid, , Spain
Valencia, , Spain
Novi Sad, , Serbia
Great Yarmouth, Norfolk, United Kingdom
Victoria, British Columbia, Canada
Cordoba, , Argentina
Braga, , Portugal
Belgrade, , Serbia
Lisboa, , Portugal
Kragujevac, , Serbia
Coimbra, , Portugal
Genova, Liguria, Italy
Milano, Lombardia, Italy
Vigo, Pontevedra, Spain
Milano, Lombardia, Italy
Stamford, Connecticut, United States
Oswiecim, , Poland
Ajax, Ontario, Canada
Cincinnati, Ohio, United States
Río Cuarto, Córdoba, Argentina
Firenze, Toscana, Italy
Nis, , Serbia
Novi Sad, , Serbia
Hialeah, Florida, United States
Lexington, Kentucky, United States
Ann Arbor, Michigan, United States
Norfolk, Virginia, United States
Ciudad Autonoma De Buenos Aires, Ciudad Autonoma De Buenosaires, Argentina
Pavia, Lombardia, Italy
Barcelona, , Spain
Río Cuarto, Cordoba, Argentina
Charlotte, North Carolina, United States
Gulf Breeze, Florida, United States
Commack, New York, United States
San Antonio, Texas, United States
Rosario, Santa Fe, Argentina
Penticton, British Columbia, Canada
Milano, Lombardia, Italy
Baltimore, Maryland, United States
Charlotte, North Carolina, United States
Glasgow, Glasgow City, United Kingdom
Porto Covo, Setúbal, Portugal
Pisa, Toscana, Italy
Munro, Buenos Aires, Argentina
San Miguel De Tucuman, Tucuman, Argentina
Roma, Lazio, Italy
Pavia, Lombardia, Italy
Tepetlacalco, , Mexico
Coimbra, , Portugal
Eskisehir, , Turkey
Warszawa, Mazowieckie, Poland
Akron, Ohio, United States
Norfolk, Virginia, United States
Barracas, Ciudad Autonoma De Buenosaires, Argentina
Pisa, Toscana, Italy
Porto Covo, Setúbal, Portugal
Braga, , Portugal
San Miguel De Tucuman, Tucumán, Argentina
Ciudad Autonoma De Buenos Aires, Ciudad Autonoma De Buenosaires, Argentina
Rosario, Santa Fe, Argentina
Fatih/Istanbul, , Turkey
New Berlin, Wisconsin, United States
Eskisehir, , Turkey
Mersin, , Turkey
Ciudad Autónoma De Buenos Aires, Ciudad Autónoma De Buenosaires, Argentina
Porto Covo, , Portugal
Porto Covo, Setúbal, Portugal
Coimbra, , Portugal
Barracas, Ciudad Autónoma De Buenosaires, Argentina
Roma, Lazio, Italy
Bayraklı, Izmir, Turkey
London, Ontario, Canada
Edinburgh, Midlothian, United Kingdom
Río Cuarto, , Argentina
Ciudad Autónoma De Buenos Aires, , Argentina
San Miguel De Tucuman, , Argentina
Edinburgh, Midlothian, United Kingdom
Porto Covo, , Portugal
Barracas, , Argentina
Lublin, , Poland
Warszawa, , Poland
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Study Director
LundbeckClinicalTrials@Lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported